Senate 'Cures' Companion Advances; Funding Unclear
This article was originally published in Scrip
A set of 19 bills aimed at improving the efficiency and pace at which the FDA and the National Institutes of Health (NIH) do their work is now on its way the full Senate for consideration after the chamber's Health, Education, Labor and Pensions (HELP) Committee agreed during an April 6 markup session on the remaining pieces of legislation.
You may also be interested in...
The firm is developing a novel class of antibacterials that could enable shelved agents for Gram-positive infections to reach and kill Gram-negative bacteria.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.